公司始终坚持战略变革延续，聚焦数字慢病管理领域，推动公司中长期战略规划与年度经营计划实施落 地。公司 2025 年度预计归属于上市公司股东的净利润较上年同期增长32.00%至 38.52%。报告期内，公 司持续优化现有业务、产品结构，积极提升高盈利客户占比，带动整体综合毛利率实现稳步提升。通过 内部运营的精细化管理，全面持续推进降本增效、优化资源配置，推动经营效率持续性改善。同时通过 优化应收账款管理机制、加强存货管理提高资产运营效率，最终实现利润的稳步增长。报告期内公司应 收账款周转率和存货周转率等运营能力指标得到有效提升，公司整体盈利水平显著提升。报告期内，非 经常性损益对公司净利润的影响金额预计为人民币630 万元。 格隆汇1月27日丨乐心医疗(300562.SZ)公布，预计2025年归属于上市公司股东的净利润8,100万元～ 8,500万元，比上年同期增长32.00%～38.52%，扣除非经常性损益后的净利润7,500万元～7,900万元，比 上年同期增长33.98%～41.13%。 ...

Core Viewpoint - 乐心医疗 reported a revenue of 521 million yuan in the first half of 2025, representing a year-on-year growth of 4.57%, and a net profit attributable to shareholders of 42.29 million yuan, up 21.35% year-on-year, alongside a cash dividend proposal of 1.3 yuan per 10 shares [1] Group 1: Financial Performance - The company achieved a revenue of 521 million yuan, marking a 4.57% increase compared to the previous year [1] - The net profit attributable to shareholders reached 42.29 million yuan, reflecting a year-on-year growth of 21.35% [1] - A cash dividend of 1.3 yuan per 10 shares is proposed for all shareholders [1] Group 2: Product Development and Innovation - The company has extended its product layout, successfully advancing the smart ring project, which integrates multiple monitoring functions such as heart rate, blood oxygen, sleep, and atrial fibrillation [1] - High-end differentiated products like the auscultation blood pressure monitor and ECG blood pressure monitor are progressing well [1] - Several forward-looking products are in the pre-research phase, and high-end customized projects for multi-modal blood testing have made phased progress [1][2] Group 3: Technological Advancements - The company has deepened its algorithm barriers, completing local deployment of PPG diagnosis, PPG-ECG fusion algorithms, and ECG-CMR mapping algorithms, enhancing the controllability and stability of core algorithms [2] - Multi-sensor and multi-hardware device integration technology has been developed to optimize data collection, improving the accuracy of physiological monitoring [2] - Efforts to address power consumption challenges include architecture optimization and low-power technology development, leading to reduced standby and operational power consumption [2] Group 4: Customer Expansion and Market Presence - The company has made significant progress in key new projects, strengthening long-term partnerships with major clients while expanding its customer base among medium-sized digital chronic disease management service providers [3] - In international markets, the company focuses on local certification of products and platforms in Europe and the Middle East, while enhancing brand exposure in emerging markets through various exhibitions [3] - Active participation in major domestic and international medical exhibitions has increased the brand's visibility and influence globally [3]